Alterity Therapeutics Ltd (PRNAF) SEC Filings — 2024
50 SEC filings for Alterity Therapeutics Ltd (PRNAF) in 2024.
Filings
- Alterity Therapeutics Files 6-K, Incorporates Filings — 6-K · Dec 31, 2024
- Alterity Therapeutics Completes Phase 2 Trial — 6-K · Dec 4, 2024
- Alterity Therapeutics Files 6-K, Incorporates AGM Address — 6-K · Nov 22, 2024
- Alterity Therapeutics Reports Company Secretary Change — 6-K · Nov 19, 2024
- Alterity Therapeutics Files 6-K, Presents MSA Data — 6-K · Nov 12, 2024
- Alterity Therapeutics Unveils Novel Mechanism for ALT-100 — 6-K · Nov 6, 2024
- Alterity Therapeutics Files Q1 FY25 Cash Flow Report — 6-K · Oct 31, 2024
- Alterity Therapeutics Files 6-K, Incorporates by Reference — 6-K · Oct 23, 2024
- Alterity Therapeutics to Speak at Maxim Healthcare Conference — 6-K · Oct 15, 2024
- Alterity Therapeutics Presents New Neuroprotection Data for ATH4 — 6-K · Oct 11, 2024
- Alterity Therapeutics Files 6-K, Cites Share Registry Change — 6-K · Oct 4, 2024
- Alterity Therapeutics Presents Data at Alzheimer's Conference — 6-K · Oct 2, 2024
- Alterity Therapeutics Appoints New CFO — 6-K · Sep 30, 2024
- Alterity Therapeutics Files 2024 Annual Report — 20-F · Sep 26, 2024
- Alterity Therapeutics to Present ATH434 Data at International Congress — 6-K · Sep 23, 2024
- Alterity Therapeutics Files Director Interest Notice — 6-K · Sep 20, 2024
- Alterity Therapeutics Files 6-K, Notifies of Security Cessation — 6-K · Sep 3, 2024
- Alterity Therapeutics Files 6-K, Incorporates Preliminary Report — 6-K · Aug 29, 2024
- Alterity Therapeutics Files 6-K on Security Cessation — 6-K · Aug 1, 2024
- Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report — 6-K · Jul 31, 2024
- Alterity Therapeutics to Present at MST Financial Webinar — 6-K · Jul 24, 2024
- Alterity Therapeutics Files 6-K for Security Quotation Application — 6-K · Jul 19, 2024
- Alterity Therapeutics Files 6-K for Security Issuance — 6-K · Jul 18, 2024
- Alterity Therapeutics Reports Positive Phase 2 Data for ATH434 — 6-K · Jul 17, 2024
- Alterity Therapeutics Reports Trading Halt — 6-K · Jul 15, 2024
- Alterity Therapeutics Files 6-K, Incorporates into S-8/F-3 Filings — 6-K · Jul 1, 2024
- Alterity Therapeutics to Present at Life Sciences Webinar — 6-K · Jun 13, 2024
- Alterity Therapeutics Presents New bioMUSE Study Data — 6-K · May 31, 2024
- Alterity Therapeutics Reports Cessation of Securities — 6-K · May 23, 2024
- Alterity Therapeutics Phase 2 Trial Continues as Planned — 6-K · May 9, 2024
- Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report — 6-K · Apr 30, 2024
- Alterity Therapeutics Files 6-K, Presents ATH434 Data — 6-K · Apr 29, 2024
- Alterity Therapeutics Data Featured at AAN Meeting — 6-K · Apr 17, 2024
- Alterity Therapeutics Files 6-K, Incorporates Securities Application — 6-K · Apr 15, 2024
- Alterity Therapeutics Files 6-K on EGM Results — 6-K · Apr 12, 2024
- Alterity Therapeutics Gets $3.9M R&D Tax Refund — 6-K · Mar 26, 2024
- Alterity Therapeutics Files 6-K, Incorporates into Registration Statements — 6-K · Mar 15, 2024
- Alterity Therapeutics Files 6-K for Security Quotation — 6-K · Mar 4, 2024
- Alterity Therapeutics Files 6-K, Incorporates Half-Yearly Report — 6-K · Feb 29, 2024
- Alterity Therapeutics Raises $3.25M AUD in Placement — 6-K · Feb 23, 2024
- Alterity Therapeutics Halts Trading, Citing Exhibit 99.1 — 6-K · Feb 22, 2024
- Alterity to Present New Data at AAN 2024 Annual Meeting — 6-K · Feb 20, 2024
- Alterity Therapeutics Enters Sales Agreement — 6-K · Feb 15, 2024
- Alterity Phase 2 Trial On Track, DMC Recommends Continuation — 6-K · Feb 6, 2024
- Alterity Therapeutics Completes Securities Purchase Plan — 6-K · Feb 2, 2024
- Alterity Completes ATH434 Phase 2 Enrollment, Boosts Cash to A$12.3M — 6-K · Jan 31, 2024
- Alterity Therapeutics: ATH434 Study Data Expected 1H 2024, Study Completion Nov 2024 — 6-K · Jan 22, 2024
- ALTERITY THERAPEUTICS: 457M NEW OPTIONS TO BE QUOTED ON ASX — 6-K · Jan 18, 2024
- Alterity Launches SPP, Institutional Backing Guarantees Capital Raise — 6-K · Jan 11, 2024
- Alterity Therapeutics Dispatches SPP Documents to Shareholders — 6-K · Jan 10, 2024